Safety profile of iloperidone: A pooled analysis of 6-week acute-phase pivotal trials

Journal of Clinical Psychopharmacology

Volumn 28, Issue 7 SUPPL. 1, 2008, Pages

  Weiden, Peter J ^a   Cutler, Andrew J ^b   Polymeropoulos, Mihael H ^c   Wolfgang, Curt D ^c  

^a Center for Cognitive Medicine   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Vanda Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; ILOPERIDONE; PLACEBO; RISPERIDONE;

ACUTE DISEASE; ADULT; AGED; AGITATION; AKATHISIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DELUSION; DIZZINESS; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSARTHRIA; DYSKINESIA; DYSPEPSIA; DYSTONIA; EDEMA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; FLATULENCE; GAIT DISORDER; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERSALIVATION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MUSCLE RIGIDITY; NAUSEA; NEUROLOGIC DISEASE; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRIAPISM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT INTERVAL; QT PROLONGATION; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TONGUE PARALYSIS; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; LONG QT SYNDROME; MALE; MIDDLE AGED; PATIENT DROPOUTS; PIPERIDINES; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 40849102838     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181694f5a     Document Type: Article

References (26)

1. Luft B, Taylor D. A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin Pharmacother. 2006;7:1739-1748.
2. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21:589-598.
3. Newcomer JW. Metabolic disturbances associated with antipsychotic use. J Clin Psychiatry. 2001;62(suppl 27):3-4.
4. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68(suppl 4):8-13.
5. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64:2291-2314.
6. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
7. Friedman JH. Atypical antipsychotics in the EPS-vulnerable patient. Psychoneuroendocrinology. 2003;28(suppl 1):39-51.
8. Lehman AF, Lieberman JA, Dixon LB, et al. Practice Guideline for the Treatment of Patients With Schizophrenia. 2nd ed. Arlington, VA: American Psychiatric Association; 2006.
9. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
10. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
11. Kalkman HO, Feuerbach D, Lotscher E, et al. Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors. Life Sci. 2003;73:1151-1159.
12. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 2001;25:904-914.
13. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29-39.
14. Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28:S20-S28.
15. Potkin SG, Litman RE, Torres R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28:S4-S11.
16. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76:247-265.
17. Fridericia LS. The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease. Acta Med Scand. 1920;53:469-486.
18. Fridericia LS. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. Ann Noninvasive Electrocardiol. 2003;8:343-351.
19. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
20. Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008;28:S29-S35.
21. Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry. 2004;65:1607-1618.
22. Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother. 2007;7:829-839.
23. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158:1774-1782.
24. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21:911-936.
25. Geodon [package insert]. New York, NY: Pfizer; 2007.
26. Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev. 2007;13:137-177.